Candidate Compounds Covid19

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(68 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
{{pnc}}
+
{{gohome}}
 +
{{ft|P}}
 +
  '''CHERRYPICKING STUDIES IS NOT SCIENCE
 +
{{qt|Reviews on covid drug development}}
  
current items will be put into the subsections.
 
subsections with contents are marked ''with content''.
 
the others are pending data.
 
  
*[[reviews on covid drug development]] ''with content''
+
*'''[[scouting ideas]]'''
*
+
  
*[[Patients on biologicals]]
+
*'''[[PHA Biologicals]]'''
*[[HMGB1, RAGE]]
+
*[[pre-Interleukin 6]] ''with content''
+
*[[post-Interleukin 6]]
+
*[[pre-TNFalpha]]
+
*[[post-TNFalpha]]
+
*[[pre-Interleukin 17]]
+
*[[post-Interleukin 17]]
+
*[[pre-Interleukin 1]]
+
*[[post-Interleukin 1]]
+
*[[Inflammasome]]
+
  
*[[NK-kappaB]]
+
*'''[[PHA conventional pharmacology]]'''
*[[STAT 3]]
+
*[[JAK Janus Kinase]]
+
*[[Corticosteroids]]
+
*[[Cytokine absorbers]]
+
*[[Target Complement system]]
+
*[[Target Extracellular traps]]
+
*[[Anticoagulant in covid19]]
+
*[[Antioxidants]]
+
*[[Stem cells]]
+
*[[MDSC cells]]
+
  
 +
*'''[[PHA retargeted compounds]]'''
  
 +
*'''[[PHA antivirals by mechanism]]'''
  
*
+
*'''[[PHA pharmacophore by screened target]]'''
*[[Hydroxychloroquine]] ''with content''
+
*
+
  
*[[AV Remdesivir]]
+
*'''[[PHA ImmunoNutrients]]
*[[AV Lopinavir]]
+
*[[AV Ivermectin]]
+
*[[Interferons]]
+
*[[Vitamin D]]
+
  
*[[Statins]]
+
*'''[[PHA compl altern natural]]'''
*[[Anorganic nutrients Magnesium]]
+
*[[Anorganic nutrients Selenium]]
+
*[[Anorganic nutrients Zinc]]
+
  
 +
*'''[[PHA within indications compounds]]'''
  
 +
*'''[[PHA Serum products]]'''
  
*[[Traditional Chinese Medicine]]
+
*'''[[PHA Vaccination]]'''
*[[Natural compounds]]
+
*[[Retargeted single compounds]]
+
  
*[[Target ACE2, Spike protein]]
+
PHA related options:
*[[Target TMPRSS2, Spike protein]]
+
*[[Reconvalescent blood products, Passive vaccine]] ''with content''
+
*[[Plasmapheresis]]
+
  
*[[Immunodeviation]] e.g. by adjuvants or other vaccinations
+
*[[Radiation therapy]]
*[[Active vaccine]] ''with cotent''
+
*[[Phototherapy]]
 +
*[[Electric fields]]
 +
*[[Treatment other concepts]]
  
  
{{tp|p=32162456|t=2020. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1 3 Billion Compounds |pdf=|usr=}}
+
A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
 +
  This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
 +
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
 +
Paper is (not yet in PubMed) :
  
 +
*'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]'''
 +
credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today.
 +
based on e.g.
  
'''Icatibant''' bradykinin antagonist
+
{{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}}
{{tp|p=32359101|t=2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications |pdf=|usr=}}
+
  
'''Arbidol''' retarget influenza
+
=======================================================================================
{{tp|p=32373347|t=2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro |pdf=|usr=}}
+
  
'''Macrolide antibiotics'''
+
COVID19 is now a CURABLE disease !!!
{{tp|p=32249257|t=2020. Macrolide treatment for COVID-19: Will this be the way forward?|pdf=|usr=}}
+
  
'''Oleoylethanolamide'''
+
  =======================================================================================
{{tp|p=32327293|t=ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19 |pdf=|usr=}}
+
 
+
'''Metronidazole''' retarget
+
{{tp|p=32259129|t=2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen |pdf=|usr=}}
+
 
+
'''Glutathione GSH''' antioxidant
+
*[https://nypost.com/2020/05/09/new-york-mom-with-coronavirus-saved-by-medical-student-son/ found in a forrest gump mode]
+
*[https://www.sciencedirect.com/science/article/pii/S2213007120301350 Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases]
+
 
+
'''Chlorpromazine''' retarget
+
*[https://www.biorxiv.org/content/10.1101/2020.05.05.079608v1 paper]
+
 
+
'''Zinc''' add-on
+
*[https://www.sciencedirect.com/science/article/pii/S0306987720306435 call for trial]
+
 
+
'''Selenium'''
+
{{tp|p=32342979|t=ä. Association between regional selenium status and reported outcome of COVID-19 cases in China |pdf=|usr=}}
+
 
+
'''Remdesivir''' retarget
+
*[https://gab.com/Remnant601/posts/104122987152232660 one hospital on...]
+
{{tp|p=32283108|t=ä. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites |pdf=|usr=}}
+
{{tp|p=32020029|t=2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro |pdf=|usr=}}
+
 
+
'''Lauric acid''' nat. compd.
+
*[https://www.icp.org.ph/2020/01/the-potential-of-coconut-oil-and-its-derivatives-as-effective-and-safe-antiviral-agents-against-the-novel-coronavirus-ncov-2019/ call for trial]
+
 
+
'''Nicotine''' nat. toxin
+
*[https://www.usatoday.com/story/news/factcheck/2020/05/03/covid-19-fact-check-caution-urged-study-virus-smoking/3055378001/ france]
+
 
+
'''Niclosamide'''
+
{{tp|p=32125140|t=ä. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential |pdf=|usr=}}
+
 
+
'''Microbiome as target'''
+
{{tp|p=32356654|t=ä. Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles |pdf=|usr=}}
+
 
+
'''ACE2 as target'''
+
{{tp|p=32286790|t=ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32333836|t=ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 |pdf=|usr=}}
+
 
+
 
+
'''Garlic extracts'''
+
{{tp|p=32363255|t=ä. Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil |pdf=|usr=}}
+
 
+
'''Dipyridamole''' retarget
+
{{tp|p=32318327|t=ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19 |pdf=|usr=}}
+
 
+
'''stem cells'''
+
{{tp|p=32257554|t=2020. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia |pdf=|usr=}}
+
{{tp|p=32257537|t=2020. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia |pdf=|usr=}}
+
{{tp|p=32283815|t=2020. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use |pdf=|usr=}}
+
 
+
 
+
'''Ivermectin'''
+
{{tp|p=32330482|t=ä. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an  FDA warning, two letters to the editor and the authors  responses |pdf=|usr=}}
+
 
+
'''Various Leads'''
+
*[https://theconversation.com/we-found-and-tested-47-old-drugs-that-might-treat-the-coronavirus-results-show-promising-leads-and-a-whole-new-way-to-fight-covid-19-136789 9 retargeted: ternatin4, zotatifin, plitidepsin; haloperidol, melperone, clemastine, cloperastine, pb28, progesterone]
+
*[https://doi.org/10.1038/s41586-020-2286-9 paper in nature]
+
{{tp|p=32251767|t=2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro |pdf=|usr=}}
+
 
+
 
+
'''Interferons'''
+
{{tp|p=32275914|t=2020. Type 1 interferons as a potential treatment against COVID-19 |pdf=|usr=}}
+
{{tp|p=32360182|t=2020. Antiviral activities of type I interferons to SARS-CoV-2 infection |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
{{tp|p=32241793|t=2020. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies |pdf=|usr=}}
+
 
+
 
+
 
+
'''Glucocorticoids'''
+
 
+
{{tp|p=32149773|t=ä. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial |pdf=|usr=}}
+
 
+
'''CRISPR genome editing technology'''
+
{{tp|p=32353252|t=ä. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza |pdf=|usr=}}
+
 
+
'''Virus interference'''
+
{{tp|p=32071427|t=2020. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses |pdf=|usr=}}
+
 
+
 
+
'''Antiviral agents Covid19'''
+
{{tp|p=32231345|t=2020. Inhibition of SARS-CoV-2 (previously 2019-nCoV)infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high  capacity to mediate membrane fusion |pdf=|usr=}}
+
 
+
 
+
 
+
'''resilience enhancement'''
+
{{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
+
{{tp|p=32311498|t=ä. The impact of nutrition on COVID-19 susceptibility and long-term consequences |pdf=|usr=}}
+
{{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency  and Similar Future Global Health Threats |pdf=|usr=}}
+
 
+
'''psychoneuroimmunology'''
+
{{tp|p=32234338|t=ä. Using psychoneuroimmunity against COVID-19 |pdf=|usr=}}
+
 
+
'''cannabinoids'''
+
{{tp|p=32360437|t=ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?|pdf=|usr=}}
+
 
+
 
+
'''Complementary & Traditional chinese medicine & Ethnopharm'''
+
{{tp|p=32245701|t=ä. Is traditional Chinese medicine useful in the treatment of COVID-19?|pdf=|usr=}}
+
{{tp|p=32233641|t=2020. Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19 |pdf=|usr=}}
+
*[https://www.aa.com.tr/en/africa/madagascar-slams-who-for-not-endorsing-its-herbal-cure/1836905 madagascar herbs]
+
{{tp|p=32229706|t=2020. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?|pdf=|usr=}}
+
{{tp|p=32037389|t=2020. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment |pdf=|usr=}}
+
{{tp|p=32334064|t=ä. Ayurveda and COVID-19: where psychoneuroimmunology and the meaning response meet |pdf=|usr=}}
+
{{tp|p=32361935|t=ä. Traditional Chinese and Western Medicines Jointly Beat COVID-19 Pandemic |pdf=|usr=}}
+
{{tp|p=32065348|t=ä. Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs |pdf=|usr=}}
+
{{tp|p=32308732|t=2020. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China |pdf=|usr=}}
+
 
+
'''Exercise'''
+
{{tp|p=32311497|t=ä. The immunological case for staying active during the COVID-19 pandemic |pdf=|usr=}}
+
 
+
'''Topical agents''' opening up the world of nano...
+
*[https://www.dailymail.co.uk/sciencetech/article-8315269/Commercial-mouthwash-prevent-COVID-19-transmission-scientists-say.html on mouth rinses]
+
 
+
 
+
 
+
 
+
 
+
 
+
----
+
 
+
 
+
 
+
{{tp|p=32272008|t=2020. Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2 |pdf=|usr=}}
+
 
+
{{tp|p=32272196|t=2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology |pdf=|usr=}}
+
{{tp|p=32247038|t=2020. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 |pdf=|usr=}}
+
{{tp|p=32222466|t=2020. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China |pdf=|usr=}}
+
{{tp|p=32360516|t=ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 |pdf=|usr=}}
+
 
+
{{tp|p=32335290|t=2020. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32266375|t=ä. Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality |pdf=|usr=}}
+
 
+
{{tp|p=32301957|t=ä. Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32344167|t=ä. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study |pdf=|usr=}}
+
{{tp|p=32305181|t=ä. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection |pdf=|usr=}}
+
{{tp|p=32360083|t=ä. Modulation of Hb-O2 affinity to improve hypoxemia in COVID-19 patients |pdf=|usr=}}
+
 
+
{{tp|p=32277367|t=ä. Rheumatologists? perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets |pdf=|usr=}}
+
{{tp|p=32373721|t=2020. Low dose lung radiotherapy for COVID-19 pneumonia  The rationale for a cost-effective anti-inflammatory treatment |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32264963|t=2020. A new clinical trial to test high-dose vitamin C in patients with COVID-19 |pdf=|usr=}}
+
 
+
 
+
 
+
{{tp|p=32241301|t=2020. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19 |pdf=|usr=}}
+
{{tp|p=32226695|t=ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32318324|t=ä. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32360420|t=ä. Cytokine storm intervention in the early stages of COVID-19 pneumonia |pdf=|usr=}}
+
 
+
 
+
 
+
{{tp|p=32335366|t=2020. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis |pdf=|usr=}}
+
{{tp|p=32333972|t=ä. Letter to the Editor in response to the article ?COVID-19 and diabetes: Can DPP4  inhibition play a role?? |pdf=|usr=}}
+
{{tp|p=32333966|t=2020. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications |pdf=|usr=}}
+
{{tp|p=32333969|t=ä. Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? ? GLP-1 Might Play One Too |pdf=|usr=}}
+
{{tp|p=32283128|t=ä. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?|pdf=|usr=}} ''on ace2 via adam17, nfkb via dpp4''
+
 
+
 
+
 
+
{{tp|p=32378648|t=2020. Rapid review for the anti-coronavirus effect of remdesivir |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
{{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32249203|t=ä. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and  rapid translational development |pdf=|usr=}}
+
 
+
{{tp|p=32379923|t=2020. Is BCG vaccination causally related to reduced COVID-19 mortality?|pdf=|usr=}}
+
{{tp|p=32333818|t=2020. COVID-19: lambda interferon against viral load and hyperinflammation |pdf=|usr=}}
+
 
+
{{tp|p=32228222|t=2020. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension |pdf=|usr=}}
+
 
+
{{tp|p=C7118608|t=ä. A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System |pdf=|usr=}}
+
{{tp|p=32065055|t=2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody |pdf=|usr=}}
+
{{tp|p=32346491|t=ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study |pdf=|usr=}}
+
{{tp|p=32292627|t=ä. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32347925|t=ä. Statin therapy in COVID-19 infection |pdf=|usr=}}
+
 
+
{{tp|p=32337546|t=ä. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?|pdf=|usr=}}
+
{{tp|p=32282032|t=ä. Neprilysin inhibitor?angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients |pdf=|usr=}}
+
{{tp|p=32285293|t=ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV |pdf=|usr=}}
+
{{tp|p=C7129866|t=ä. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19 |pdf=|usr=}}
+
{{tp|p=32341100|t=2020. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective |pdf=|usr=}}
+
{{tp|p=32265310|t=ä. Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19 |pdf=|usr=}}
+
{{tp|p=32271462|t=2020. Inositol and pulmonary function  Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?|pdf=|usr=}}
+
{{tp|p=32271456|t=2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease  2019 |pdf=|usr=}}
+
{{tp|p=32271454|t=2020. Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19 |pdf=|usr=}}
+
{{tp|p=32329881|t=2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience |pdf=|usr=}}
+
{{tp|p=32329879|t=2020. (Naturlal products: )An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections |pdf=|usr=}}
+
{{tp|p=32327396|t=ä. COVID-19 and Bacillus Calmette-Guerin: What is the Link?|pdf=|usr=}}
+
{{tp|p=32279655|t=2020. Can Hepatitis A Vaccine Provide Protection Against COVID-19?|pdf=|usr=}}
+
 
+
{{tp|p=32329380|t=2020. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia |pdf=|usr=}}
+
{{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
+
{{tp|p=32117569|t=2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China |pdf=|usr=}}
+
 
+
 
+
 
+
{{tp|p=32374074|t=2020. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease |pdf=|usr=}}
+
 
+
{{tp|p=32251729|t=ä. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design |pdf=|usr=}}
+
{{tp|p=32363144|t=ä. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin |pdf=|usr=}}
+
 
+
{{tp|p=32247692|t=ä. Faecal-oral transmission of SARS-COV-2: practical implications |pdf=|usr=}}
+
{{tp|p=32367287|t=ä. New evidence of SARS-CoV-2 transmission through the ocular surface |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32251365|t=ä. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy |pdf=|usr=}}
+
{{tp|p=32375153|t=2020. HMGB1: A Possible Crucial Therapeutic Target for COVID-19?|pdf=|usr=}}
+
{{tp|p=32186952|t=2020. COVID-19, an emerging coronavirus infection: advances and prospects in designing  and developing vaccines, immunotherapeutics, and therapeutics |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32362644|t=2020. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32366728|t=2020. Medical Education During the COVID-19 Pandemic: A Single Institution Experience |pdf=|usr=}}
+
{{tp|p=32366726|t=2020. Management of Asthma in Children during COVID-19 Pandemic |pdf=|usr=}}
+
{{tp|p=32366725|t=2020. COVID -19 Pandemic: The Challenges for Pediatric Oncology |pdf=|usr=}}
+
 
+
{{tp|p=32358227|t=2020. Demystifying BCG Vaccine and COVID-19 Relationship |pdf=|usr=}}
+
 
+
{{tp|p=32238614|t=2020. Measles Immunization: Worth Considering Containment Strategy for SARS-CoV-2 Global Outbreak |pdf=|usr=}}
+
{{tp|p=32321620|t=ä. Corticosteroid use for 2019-nCoV infection: A double-edged sword |pdf=|usr=}}
+
{{tp|p=32341599|t=2020. Is Immuno-modulation the Key to COVID-19 Pandemic?|pdf=|usr=}}
+
 
+
 
+
{{tp|p=32328406|t=ä. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32342098|t=ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib |pdf=|usr=}}
+
{{tp|p=32372149|t=ä. SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?|pdf=|usr=}}
+
 
+
{{tp|p=32272396|t=ä. The Possible of Immunotherapy for COVID-19: a Systematic Review |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32234466|t=ä. Coronavirus disease 2019 (COVID-19): current status and future perspectives |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32259575|t=ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF  COVID 19 |pdf=|usr=}}
+
{{tp|p=32361028|t=ä. ?Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ? |pdf=|usr=}}
+
 
+
{{tp|p=32251731|t=ä. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection |pdf=|usr=}}
+
{{tp|p=32360231|t=ä. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?|pdf=|usr=}}
+
{{tp|p=32335281|t=ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19 |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
{{tp|p=32283177|t=ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in  SARS-CoV-2 Infections |pdf=|usr=}}
+
 
+
{{tp|p=32179150|t=ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?|pdf=|usr=}}
+
{{tp|p=32147516|t=ä. Arguments in favour of remdesivir for treating SARS-CoV-2 infections |pdf=|usr=}}
+
 
+
{{tp|p=32226290|t=2020. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19 |pdf=|usr=}}
+
{{tp|p=32226288|t=2020. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New  Coronavirus (SARS-CoV-2): A Review and Perspective |pdf=|usr=}}
+
 
+
{{tp|p=32300868|t=ä. Balneotherapy and human immune function in the era of COVID-19 |pdf=|usr=}}
+
{{tp|p=32321655|t=ä. An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients |pdf=|usr=}}
+
{{tp|p=32251768|t=2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |pdf=|usr=}}
+
 
+
*[https://www.infowars.com/experts-suggest-90-million-oxford-university-coronavirus-vaccine-doesnt-work/ Oxford vaccine failed in monkeys]
+
{{tp|p=32305009|t=ä. Investigating hypothiocyanite against SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32173576|t=2020. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression |pdf=|usr=}}
+
 
+
{{tp|p=32354030|t=2020. Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work |pdf=|usr=}}
+
 
+
{{tp|p=32353978|t=2020. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design |pdf=|usr=}}
+
 
+
{{tp|p=32368489|t=2020. The pathogenesis and alternative treatment of SARS-CoV2 |pdf=|usr=}}
+
{{tp|p=32289016|t=2020. Herbal medicine and pattern identification for treating COVID-19: a rapid review  of guidelines |pdf=|usr=}}
+
{{tp|p=32125455|t=ä. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target |pdf=|usr=}}
+
{{tp|p=32347443|t=ä. Camostat mesilate therapy for COVID-19 |pdf=|usr=}}
+
{{tp|p=32333086|t=ä. Remdesivir bei Patienten mit schwerer COVID-19 |pdf=|usr=}}
+
{{tp|p=32378817|t=2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients |pdf=|usr=}}
+
*[https://www.nature.com/articles/d41573-020-00073-5 Nature: The COVID-19 vaccine development landscape]
+
{{tp|p=32283237|t=ä. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?|pdf=|usr=}}
+
{{tp|p=32278797|t=ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32339701|t=ä. Potential role of Janus kinase inhibitors in COVID-19 |pdf=|usr=}}
+
{{tp|p=32344070|t=ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32283123|t=ä. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus  Disease 2019) Treatment |pdf=|usr=}}
+
{{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}}
+
{{tp|p=32361744|t=ä. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease |pdf=|usr=}}
+
{{tp|p=32196083|t=ä. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression |pdf=|usr=}}
+
{{tp|p=32317220|t=ä. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32284326|t=2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency |pdf=|usr=}}
+
{{tp|p=32094225|t=2020. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase  from Middle East respiratory syndrome coronavirus |pdf=|usr=}}
+
 
+
{{tp|p=32306862|t=2020. Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes |pdf=|usr=}}
+
{{tp|p=32266873|t=2020. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2?-O-ribose methyltransferase |pdf=|usr=}}
+
{{tp|p=32238078|t=2020. In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel |pdf=|usr=}}
+
 
+
{{tp|p=32374474|t=2020. Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
 
+
{{tp|p=32352407|t=2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor  antagonists |pdf=|usr=}}
+
 
+
{{tp|p=32326602|t=2020. Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19 |pdf=|usr=}}
+
{{tp|p=32326426|t=2020. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
{{tp|p=32289152|t=2020. COVID-19 and emerging viral infections: The case for interferon lambda |pdf=|usr=}}
+
{{tp|p=32302401|t=2020. Targeting potential drivers of COVID-19: Neutrophil extracellular traps |pdf=|usr=}}
+
{{tp|p=32359878|t=2020. Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32171450|t=2020. Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus |pdf=|usr=}}
+
{{tp|p=32173287|t=ä. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines |pdf=|usr=}}
+
{{tp|p=32373322|t=ä. Fighting COVID-19 with water |pdf=|usr=}}''dehydration of mucous glycans''
+
 
+
{{tp|p=32171872|t=ä. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study |pdf=|usr=}}
+
{{tp|p=32333918|t=ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact |pdf=|usr=}}
+
{{tp|p=32283153|t=ä. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1 |pdf=|usr=}}
+
{{tp|p=32362440|t=ä. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases |pdf=|usr=}}
+
 
+
{{tp|p=32293807|t=2020. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID?19: initial assessment |pdf=|usr=}}
+
{{tp|p=32307268|t=2020. Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC?MSE analysis |pdf=|usr=}}
+
{{tp|p=32122812|t=2020. Traditional Chinese medicine is a resource for drug discovery against 2019 novel  coronavirus (SARS-CoV-2) |pdf=|usr=}}
+
{{tp|p=32113846|t=ä. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus |pdf=|usr=}}
+
{{tp|p=32080993|t=2020. The Author s Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for  the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR |pdf=|usr=}}
+
{{tp|p=32080992|t=2020. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission  of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for  the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR |pdf=|usr=}}
+
{{tp|p=32056407|t=2020. Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR |pdf=|usr=}}
+
 
+
{{tp|p=32356252|t=ä. COVID-19: Therapeutics and Their Toxicities |pdf=|usr=}}
+
{{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}}
+
{{tp|p=32052466|t=2020. Potential interventions for novel coronavirus in China: A systematic review |pdf=|usr=}}
+
 
+
 
+
{{ttp|p=32205092|t=ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |pdf=|usr=}}
+
*[https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds on ivermectin]
+
 
+
 
+
{{tp|p=32331982|t=ä. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan |pdf=|usr=}}
+
{{tp|p=32236561|t=ä. Combating COVID-19 with Chloroquine |pdf=|usr=}}
+
 
+
{{tp|p=32296570|t=ä. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants? |pdf=|usr=}}
+
{{tp|p=32346490|t=ä. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase |pdf=|usr=}}
+
{{tp|p=32324533|t=2020. Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients |pdf=|usr=}}
+
 
+
{{tp|p=32291198|t=2020. Impact of Nutrition and Diet on COVID-19 Infection and Implications for Kidney Health and Kidney Disease Management |pdf=|usr=}}
+
 
+
{{tp|p=32353597|t=ä. SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy |pdf=|usr=}}
+
{{tp|p=32281481|t=2020. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review |pdf=|usr=}}
+
{{tp|p=32370758|t=2020. SARS-CoV-2 RNA polymerase as target for antiviral therapy |pdf=|usr=}}
+
 
+
{{tp|p=32313848|t=ä. Precision medicine in COVID-19: IL-1 beta a potential target |pdf=|usr=}}
+
 
+
 
+
 
+
{{tp|p=32321635|t=2020. Old and new antirheumatic drugs for the treatment of COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32317113|t=2020. COVID-19 therapeutic options for patients with kidney disease |pdf=|usr=}}
+
{{tp|p=32354636|t=ä. Blockade of SARS-CoV-2 infection by recombinant soluble ACE2 |pdf=|usr=}}
+
{{tp|p=32367812|t=2020. Fyrsta meethfereth meeth tocilizumab vieth COVID-19 herlendis - sjukratilfelli|pdf=|usr=}}
+
{{tp|p=32365215|t=2020. Behandling med 4-aminokinoliner vid covid-19 kan ge allvarliga biverkningar |pdf=|usr=}}
+
{{tp|p=32278362|t=2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed |pdf=|usr=}}
+
{{tp|p=32122468|t=2020. On the use of corticosteroids for 2019-nCoV pneumonia |pdf=|usr=}}
+
{{tp|p=32035018|t=2020. Reducing mortality from 2019-nCoV: host-directed therapies should be an option |pdf=|usr=}}
+
{{tp|p=32043983|t=2020. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury |pdf=|usr=}}
+
{{tp|p=32032529|t=2020. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease |pdf=|usr=}}
+
{{tp|p=32220278|t=2020. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?|pdf=|usr=}}
+
{{tp|p=32353328|t=2020. What policy makers need to know about COVID-19 protective immunity |pdf=|usr=}}
+
{{tp|p=32305088|t=2020. Flooded by the torrent: the COVID-19 drug pipeline |pdf=|usr=}}
+
{{tp|p=32278373|t=2020. Regulators split on antimalarials for COVID-19 |pdf=|usr=}}
+
{{tp|p=32339473|t=ä. Probiotics and COVID-19: one size does not fit all |pdf=|usr=}}
+
{{tp|p=32199468|t=ä. Use of antiviral drugs to reduce COVID-19 transmission |pdf=|usr=}}
+
{{tp|p=32278361|t=ä. Attention should be paid to venous thromboembolism prophylaxis in the management  of COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32325035|t=ä. Plea for multitargeted interventions for severe COVID-19 |pdf=|usr=}}
+
{{tp|p=32311322|t=ä. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19 |pdf=|usr=}}
+
{{tp|p=32311324|t=ä. Hydroxychloroquine prophylaxis for COVID-19 contacts in India |pdf=|usr=}}
+
{{tp|p=32113510|t=2020. Convalescent plasma as a potential therapy for COVID-19 |pdf=|usr=}}
+
{{tp|p=32113509|t=2020. COVID-19: combining antiviral and anti-inflammatory treatments |pdf=|usr=}}
+
{{tp|p=32304640|t=ä. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base |pdf=|usr=}}
+
{{tp|p=32368738|t=2020. Excitement around hydroxychloroquine for treating COVID-19 causes challenges for  rheumatology |pdf=|usr=}}
+
{{tp|p=32368737|t=2020. Preventing COVID-19-induced pneumonia with anticytokine therapy |pdf=|usr=}}
+
{{tp|p=32372026|t=ä. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis |pdf=|usr=}}
+
{{tp|p=32119961|t=2020. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 |pdf=|usr=}}
+
{{tp|p=32222463|t=ä. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2  RNA dependent RNA polymerase (RdRp): A molecular docking study |pdf=|usr=}}
+
{{tp|p=32251634|t=2020. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease |pdf=|usr=}}
+
{{tp|p=32217117|t=2020. COVID-19: Melatonin as a potential adjuvant treatment |pdf=|usr=}}
+
{{tp|p=32360622|t=2020. Comment on Melatonin as a potential adjuvant treatment for COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32334009|t=2020. Correspondence COVID-19: Melatonin as a potential adjuvant treatment |pdf=|usr=}}
+
{{tp|p=32278693|t=2020. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach |pdf=|usr=}}
+
{{tp|p=32340389|t=2020. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural  Products: A Virtual Screening and Molecular Modeling Study |pdf=|usr=}}
+
{{tp|p=32359771|t=ä. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32198163|t=2020. Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection |pdf=|usr=}}
+
{{tp|p=32265331|t=2020. Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein  Protects Mice from Fatal MERS-CoV Infection |pdf=|usr=}}
+
{{tp|p=32328576|t=2020. Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?|pdf=|usr=}}
+
{{tp|p=32296777|t=2020. Mesenchymal stem cells and management of COVID-19 pneumonia |pdf=|usr=}}
+
{{tp|p=32289117|t=2020. Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus |pdf=|usr=}}
+
{{tp|p=32292906|t=2020. The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis: A review |pdf=|usr=}}
+
{{tp|p=C7147214|t=ä. Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection |pdf=|usr=}}
+
{{tp|p=32352081|t=ä. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19 |pdf=|usr=}}
+
{{tp|p=32352080|t=ä. Does vitamin D status impact mortality from SARS-CoV-2 infection?|pdf=|usr=}}
+
{{tp|p=32313880|t=ä. PAK1-blockers: Potential Therapeutics against COVID-19? |pdf=|usr=}}
+
{{tp|p=32292909|t=2020. Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies |pdf=|usr=}}
+
{{tp|p=32220710|t=2020. Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32361169|t=2020. Why not consider an endothelin receptor antagonist against SARS?CoV?2?|pdf=|usr=}}
+
*''riociguat?''
+
{{tp|p=32361100|t=2020. Amantadine as a drug to mitigate the effects of COVID-19 |pdf=|usr=}}
+
{{tp|p=32353740|t=2020. Serum albumin-mediated strategy for the effective targeting of SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32353742|t=ä. Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?|pdf=|usr=}}
+
{{tp|p=32353743|t=2020. Purposing Saikosaponins for the treatment of COVID-19 |pdf=|usr=}}
+
{{tp|p=32344275|t=2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS) |pdf=|usr=}}
+
{{tp|p=32344303|t=ä. Oxytocin as a potential defence against Covid-19?|pdf=|usr=}}
+
{{tp|p=32361588|t=2020. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19 |pdf=|usr=}}
+
{{tp|p=32361099|t=2020. The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19 |pdf=|usr=}}
+
{{tp|p=32344315|t=2020. N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome |pdf=|usr=}}
+
{{tp|p=32353741|t=2020. Phytotherapeutics and SARS-CoV-2 infection: Potential role of bioflavonoids |pdf=|usr=}}
+
{{tp|p=32344313|t=ä. Can pioglitazone be potentially useful therapeutically in treating patients with  covid-19?|pdf=|usr=}}
+
{{tp|p=32344312|t=2020. Potential effect of natural and anabolizan steroids in elderly patient with COVID-19 |pdf=|usr=}}
+
{{tp|p=32344310|t=2020. Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality |pdf=|usr=}}
+
{{tp|p=32344308|t=2020. Suggesting Ritonavir against COVID-19/SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32339778|t=ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19 |pdf=|usr=}}
+
{{tp|p=32339777|t=2020. May IL-17 have a role in COVID-19 infection?|pdf=|usr=}}
+
{{tp|p=32335456|t=2020. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?|pdf=|usr=}}
+
 
+
{{tp|p=C7158785|t=ä. Convalescent plasma: A possible treatment of COVID-19 in India |pdf=|usr=}}
+
{{tp|p=32217166|t=2020. Chloroquine and COVID-19, where do we stand?? |pdf=|usr=}}
+
{{tp|p=32240719|t=ä. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection |pdf=|usr=}}
+
{{tp|p=32353355|t=ä. Testosterone, a key hormone in the context of COVID-19 pandemic |pdf=|usr=}}
+
{{tp|p=32344177|t=2020. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect |pdf=|usr=}}
+
{{tp|p=32305500|t=ä. Chloroquine paradox may cause more damage than help fight COVID-19 |pdf=|usr=}}
+
{{tp|p=32370766|t=2020. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines |pdf=|usr=}}
+
{{tp|p=32307014|t=2020. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 |pdf=|usr=}}
+
{{tp|p=32255312|t=2020. A possible probiotic (S  salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32365556|t=2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease |pdf=|usr=}}
+
{{tp|p=32316270|t=2020. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help |pdf=|usr=}}
+
{{tp|p=32231349|t=2020. Chloroquine in COVID-19: the evidence |pdf=|usr=}}
+
{{tp|p=32231348|t=2020. Emerging prophylaxis strategies against COVID-19 |pdf=|usr=}}
+
{{tp|p=32291351|t=2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data |pdf=|usr=}}
+
{{tp|p=32187464|t=ä. A Trial of Lopinavir?Ritonavir in Adults Hospitalized with Severe Covid-19 |pdf=|usr=}}
+
{{tp|p=32187463|t=ä. Covid-19 ? The Search for Effective Therapy |pdf=|usr=}}
+
{{tp|p=32275812|t=ä. Compassionate Use of Remdesivir for Patients with Severe Covid-19 |pdf=|usr=}}
+
{{tp|p=32354113|t=2020. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges |pdf=|usr=}}
+
{{tp|p=32326343|t=2020. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?|pdf=|usr=}}
+
{{tp|p=32366817|t=2020. A human monoclonal antibody blocking SARS-CoV-2 infection |pdf=|usr=}}
+
{{tp|p=32203437|t=ä. Insights from nanomedicine into chloroquine efficacy against COVID-19 |pdf=|usr=}}
+
{{tp|p=32358580|t=ä. COVID-19: a case for inhibiting IL-17?|pdf=|usr=}}
+
{{tp|p=32358579|t=ä. Will helminth co-infection modulate COVID-19 severity in endemic regions?|pdf=|usr=}}
+
{{tp|p=32296135|t=ä. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?|pdf=|usr=}}
+
{{tp|p=32355330|t=ä. Inactivated vaccine for SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32327719|t=ä. Complement as a target in COVID-19?|pdf=|usr=}}
+
{{tp|p=32346092|t=ä. Cancer therapy tool informs COVID-19 vaccines |pdf=|usr=}}
+
{{tp|p=32346094|t=ä. COVID-19 vaccine design: the Janus face of immune enhancement |pdf=|usr=}}
+
{{tp|p=32317716|t=ä. The potential danger of suboptimal antibody responses in COVID-19 |pdf=|usr=}}
+
*[https://www.biorxiv.org/content/10.1101/2020.03.22.002386v3 A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing]
+
{{tp|p=32286538|t=ä. Human antibodies can neutralize SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32332922|t=ä. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2 |pdf=|usr=}}
+
{{tp|p=32327746|t=ä. Translating IL-6 biology into effective treatments |pdf=|usr=}}
+
{{tp|p=32341531|t=ä. Could BCG be used to protect against COVID-19?|pdf=|usr=}}
+
{{tp|p=32291449|t=ä. ADAM17 inhibition may exert a protective effect on COVID-19 |pdf=|usr=}}
+
{{tp|p=32350818|t=ä. Chloroquine-induced QTc prolongation in COVID-19 patients |pdf=|usr=}}
+
 
+
{{tp|p=32322402|t=2020. Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19 |pdf=|usr=}}
+
{{tp|p=32355564|t=2020. Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome |pdf=|usr=}}
+
{{tp|p=32322397|t=2020. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance |pdf=|usr=}}
+
{{tp|p=32313660|t=2020. A short review on antibody therapy for COVID-19 |pdf=|usr=}}
+
{{tp|p=32372835|t=2020. Trials of BCG vaccine will test for covid-19 protection |pdf=|usr=}}
+
{{tp|p=32287799|t=2020. Drug trials under way |pdf=|usr=}}
+
{{tp|p=32353120|t=ä. Does Cigarette Smoking Protect Against SARS-CoV-2 Infection?|pdf=|usr=}}
+
{{tp|p=32242236|t=ä. COVID-19 and Smoking |pdf=|usr=}}
+
{{tp|p=32194995|t=2020. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines |pdf=|usr=}}
+
{{tp|p=32340216|t=2020. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections |pdf=|usr=}}
+
{{tp|p=32252338|t=2020. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths |pdf=|usr=}}
+
{{tp|p=32342019|t=ä. Exercise against SARS-CoV-2 (COVID-19): Does workout intensity matter? (A mini review of some indirect evidence related to obesity) |pdf=|usr=}}
+
{{tp|p=32258351|t=2020. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses |pdf=|usr=}}
+
{{tp|p=32258207|t=2020. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019 |pdf=|usr=}}
+
{{tp|p=32363212|t=ä. Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32292817|t=2020. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 |pdf=|usr=}}
+
{{tp|p=32284951|t=2020. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options |pdf=|usr=}}
+
{{tp|p=32214286|t=2020. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use |pdf=|usr=}}
+
{{tp|p=32098302|t=2020. Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development |pdf=|usr=}}
+
{{tp|p=32357471|t=2020. Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs |pdf=|usr=}}
+
{{tp|p=32333199|t=ä. Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19 |pdf=|usr=}}
+
{{tp|p=32307559|t=ä. Management for patients with pediatric surgical disease during the COVID-19 epidemic |pdf=|usr=}}
+
{{tp|p=32215760|t=2020. Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond |pdf=|usr=}}
+
{{tp|p=32245264|t=2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses |pdf=|usr=}}
+
{{tp|p=32290348|t=2020. COVID-19: A Brief Overview of the Discovery Clinical Trial |pdf=|usr=}}
+
{{tp|p=32371086|t=ä. The pros and cons of traditional Chinese medicines in the treatment of COVID-19 |pdf=|usr=}}
+
{{tp|p=32145402|t=2020. Traditional Chinese medicine for COVID-19 treatment |pdf=|usr=}}
+
{{tp|p=32205232|t=2020. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) |pdf=|usr=}}
+
{{tp|p=32360585|t=ä. Current targeted therapeutics against COVID-19: based on first-line experience in china |pdf=|usr=}}
+
{{tp|p=32360584|t=ä. Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2 |pdf=|usr=}}
+
{{tp|p=32360583|t=ä. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis |pdf=|usr=}}
+
{{tp|p=32360581|t=ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for  COVID-19 early management |pdf=|usr=}}
+
{{tp|p=32360580|t=ä. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-kappaB signaling pathway |pdf=|usr=}}
+
{{tp|p=32251726|t=2020. The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm  than good |pdf=|usr=}}
+
{{tp|p=32251725|t=ä. Reply to ?The use of traditional Chinese medicines to treat SARS-CoV-2 may cause  more harm than good? |pdf=|usr=}}
+
{{tp|p=32360484|t=2020. Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico  and experimental study |pdf=|usr=}}
+
{{tp|p=32360480|t=ä. Candidate drugs against SARS-CoV-2 and COVID-19 |pdf=|usr=}}
+
{{tp|p=32334052|t=2020. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection |pdf=|usr=}}
+
{{tp|p=32325127|t=2020. Darunavir does not prevent SARS-CoV-2 infection in HIV patients |pdf=|usr=}}
+
{{tp|p=32247821|t=2020. 3CLpro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials |pdf=|usr=}}
+
{{tp|p=32302707|t=ä. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?: This paper is dedicated to  Sofia Maione born during COVID-19 outbreak |pdf=|usr=}}
+
{{tp|p=32283223|t=2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32322486|t=2020. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome |pdf=|usr=}}
+
{{tp|p=32369479|t=2020. Antibody-based therapies for COVID-19: Can Europe move faster?|pdf=|usr=}}
+
{{tp|p=32343686|t=2020. Pandemic responses: Planning to neutralize SARS-CoV-2 and prepare for future outbreaks |pdf=|usr=}}
+
 
+
{{tp|p=32054787|t=2020. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection |pdf=|usr=}}
+
{{tp|p=32253318|t=2020. Effectiveness of convalescent plasma therapy in severe COVID-19 patients |pdf=|usr=}}
+
{{tp|p=32229574|t=2020. News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine |pdf=|usr=}}
+
{{tp|p=32275753|t=ä. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19 |pdf=|usr=}}
+
{{tp|p=32342871|t=ä. Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?|pdf=|usr=}}
+
{{tp|p=32342874|t=ä. Low dose radiation therapy for COVID-19 pneumonia: a double-edged sword |pdf=|usr=}}
+
{{tp|p=32327397|t=ä. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine |pdf=|usr=}}
+
{{ttp|p=32322478|t=2020. Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases |pdf=|usr=}}
+
{{tp|p=32354685|t=ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia |pdf=|usr=}}
+
 
+
{{tp|p=32239125|t=2020. Remdesivir, la esperanza antiviral frente al SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32256547|t=2020. Clinical trials on drug repositioning for COVID-19 treatment |pdf=|usr=}}
+
{{tp|p=32267301|t=ä. Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes |pdf=|usr=}}
+
{{tp|p=32232552|t=ä. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs |pdf=|usr=}}
+
{{tp|p=32124179|t=ä. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need |pdf=|usr=}}
+
{{tp|p=32376987|t=2020. Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2 expression |pdf=|usr=}}
+
{{tp|p=32278175|t=ä. COVID-19: A promising cure for the global panic |pdf=|usr=}}
+
{{tp|p=32253226|t=ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |pdf=|usr=}}
+
{{tp|p=32358203|t=ä. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir |pdf=|usr=}}
+
{{tp|p=32198291|t=2020. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved ?-ketoamide inhibitors |pdf=|usr=}}
+
{{tp|p=32321856|t=ä. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease |pdf=|usr=}}
+
{{tp|p=32347055|t=2020.  Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors  |pdf=|usr=}}
+
{{tp|p=32341331|t=2020. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia |pdf=|usr=}}
+
{{tp|p=32347054|t=2020.  Strategies for vaccine development of COVID-19  |pdf=|usr=}}
+
{{tp|p=32133159|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}}
+
{{tp|p=32366290|t=2020. Mesenchymal stem cells as a potential therapy for COVID-19 |pdf=|usr=}}
+
{{tp|p=C7110269|t=ä. COVID-19 Outbreak: an Update on Therapeutic Options |pdf=|usr=}}
+
{{tp|p=32307653|t=ä. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement |pdf=|usr=}}
+
{{tp|p=32281052|t=ä. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future |pdf=|usr=}}
+
{{tp|p=32320535|t=2020. Mesenchymal stem cells as a potential treatment for critically ill patients with  coronavirus disease 2019 |pdf=|usr=}}
+
{{tp|p=32362735|t=ä. Insights into the inhibitory potential of selective phytochemicals against Mpro of 2019-nCoV: a computer-aided study |pdf=|usr=}}
+
{{tp|p=32347963|t=2020. An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19 |pdf=|usr=}}
+
{{tp|p=32343358|t=2020. Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives |pdf=|usr=}}
+
{{tp|p=32328234|t=2020. Does the direct renin inhibitor have a role to play in attenuating severity of the outbreak coronavirus disease 2019 (COVID-19)?|pdf=|usr=}}
+
{{tp|p=32360140|t=ä. Bee venom and SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32345485|t=ä. Treatment for emerging viruses: Convalescent plasma and COVID-19 |pdf=|usr=}}
+
{{tp|p=32359789|t=ä. COVID-19 Convalescent Plasma: Now Is the Time for Better Science |pdf=|usr=}}
+
{{tp|p=32359788|t=ä. Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic |pdf=|usr=}}
+
{{tp|p=32289548|t=2020. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study |pdf=|usr=}}
+
{{tp|p=32247925|t=ä. Repurposing antimalarials and other drugs for COVID-19 |pdf=|usr=}}
+
{{tp|p=32145386|t=ä. Remdesivir as a possible therapeutic option for the COVID-19 |pdf=|usr=}}
+
{{tp|p=32334088|t=ä. SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?|pdf=|usr=}}
+
{{tp|p=32325121|t=ä. Tocilizumab: A new opportunity in the possible therapeutic arsenal against COVID-19 |pdf=|usr=}}
+
{{tp|p=32247927|t=ä. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19:  An evaluation of the evidence |pdf=|usr=}}
+
{{tp|p=32249063|t=ä. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses |pdf=|usr=}}
+
{{tp|p=32362491|t=ä. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355?359; 2020) |pdf=|usr=}}
+
{{tp|p=32294562|t=ä. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease |pdf=|usr=}}
+
{{tp|p=32371057|t=ä. Potential applications of plant biotechnology against SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32291112|t=ä. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic |pdf=|usr=}}
+
{{tp|p=32299202|t=2020. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs|pdf=|usr=}}
+
{{tp|p=32293834|t=2020. Antiviral treatment of COVID-19|pdf=|usr=}}
+
{{tp|p=32295153|t=2020. What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?|pdf=|usr=}}
+
{{tp|p=32235387|t=2020. Progress and Prospects on Vaccine Development against SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32034638|t=ä. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury |pdf=|usr=}}
+
{{tp|p=32297156|t=ä. Computational Identification of Small Interfering RNA Targets in SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32360300|t=ä. Natural product-derived phytochemicals as potential agents against coronaviruses: a review |pdf=|usr=}}
+
{{tp|p=32363219|t=ä. Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock |pdf=|usr=}}
+
{{tp|p=32106567|t=2020. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies |pdf=|usr=}}
+
{{tp|p=32098094|t=2020. Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with  the 3C-Like Protease Inhibitor GC376 |pdf=|usr=}}
+
{{tp|p=32272550|t=2020. Antiviral Agents: Discovery to Resistance |pdf=|usr=}}
+
{{tp|p=32268515|t=2020. In Silico Discovery of Candidate Drugs against Covid-19 |pdf=|usr=}}
+
{{tp|p=32357553|t=2020. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19 |pdf=|usr=}}
+
{{tp|p=32340120|t=2020. Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19 |pdf=|usr=}}
+
{{tp|p=32295237|t=2020. Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs |pdf=|usr=}}
+
{{tp|p=32313883|t=2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review) |pdf=|usr=}}
+
{{tp|p=C7118592|t=ä. Understanding of guidance for acupuncture and moxibustion interventions on COVID-19 (Second edition) issued by CAAM |pdf=|usr=}}
+
{{ttp|p=32312290|t=2020. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis |pdf=|usr=}}
+
 
+
{{tp|p=32377965|t=ä. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality |pdf=|usr=}}
+
{{tp|p=32297520|t=2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?|pdf=|usr=}}
+
{{tp|p=32297519|t=2020. COVID-19 and vitamin D?Is there a link and an opportunity for intervention?|pdf=|usr=}}
+
{{tp|p=32191676|t=2020. Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?|pdf=|usr=}}
+
{{tp|p=32286694|t=2020. Letter: Covid-19, and vitamin D  Authors  reply |pdf=|usr=}}
+
{{tp|p=32281109|t=2020. Letter: Covid-19, and vitamin D |pdf=|usr=}}
+
{{tp|p=32339299|t=2020. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?|pdf=|usr=}}
+
{{tp|p=32330314|t=2020. Is BCG vaccination affecting the spread and severity of COVID-19?|pdf=|usr=}}
+
{{tp|p=32349517|t=2020. Becoming a Faithful Defender: Traditional Chinese Medicine against Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32164424|t=2020. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic  Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease |pdf=|usr=}}
+
{{tp|p=32358817|t=2020. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle  cell disease and acute chest syndrome |pdf=|usr=}}
+
{{tp|p=32282956|t=2020. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle  cell patient successfully treated with tocilizumab |pdf=|usr=}}
+
{{tp|p=32247518|t=2020. COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?|pdf=|usr=}}
+
{{tp|p=32207983|t=2020. Covid-19 infection and mortality: a physiologist?s perspective enlightening clinical features and plausible interventional strategies |pdf=|usr=}}
+
{{tp|p=32314704|t=2020. Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency |pdf=|usr=}}
+
{{tp|p=32359210|t=2020. Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report |pdf=|usr=}}
+
{{tp|p=32324331|t=2020. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine |pdf=|usr=}}
+
{{tp|p=32274985|t=2020. Novel Coronavirus Disease (COVID-19): The Need for Immunoprevention at Industrial Scale |pdf=|usr=}}
+
{{tp|p=32352178|t=2020. Editorial: low population mortality from COVID-19 in countries south of latitude  35 degrees North-supports vitamin D as a factor determining severity  Authors  reply |pdf=|usr=}}
+
{{tp|p=32311755|t=2020. Editorial: low population mortality from COVID-19 in countries south of latitude  35 degrees North supports vitamin D as a factor determining severity |pdf=|usr=}}
+
 
+
{{tp|p=32329159|t=2020. Thoughts on What Chemists Can Contribute to Fighting SARS-CoV-2 - A Short Note on Hand Sanitizers, Drug Candidates and Outreach |pdf=|usr=}}
+
{{tp|p=32376597|t=2020. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series |pdf=|usr=}}
+
{{tp|p=32345616|t=2020. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19 |pdf=|usr=}}
+
{{tp|p=32304395|t=2020. COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support |pdf=|usr=}}
+
{{ttp|p=32349115|t=ä. Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19 |pdf=|usr=}}
+
{{tp|p=32380318|t=ä. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection |pdf=|usr=}}
+
{{tp|p=32380316|t=ä. Convalescent plasma in Covid-19: Possible mechanisms of action |pdf=|usr=}}
+
{{tp|p=32380315|t=ä. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |pdf=|usr=}}
+
{{tp|p=32376396|t=ä. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk  for candidemia?|pdf=|usr=}}
+
{{tp|p=32376395|t=ä. SARS-CoV-2 infection among patients with systemic autoimmune diseases |pdf=|usr=}}
+
{{ttp|p=32376392|t=ä. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions |pdf=|usr=}}
+
{{tp|p=32376403|t=ä. Imatinib might constitute a treatment option for lung involvement in COVID-19 |pdf=|usr=}}
+
{{ttp|p=32376394|t=ä. Immunomodulatory therapy for the management of severe COVID-19  Beyond the anti-viral therapy: A comprehensive review |pdf=|usr=}}
+
{{ttp|p=32376397|t=ä. Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view |pdf=|usr=}}
+
{{tp|p=32376398|t=ä. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in  Brescia, Italy |pdf=|usr=}}
+
{{tp|p=32361195|t=ä. SARS-CoV-2 infection complicated by inflammatory syndrome  Could high-dose human  immunoglobulin for intravenous use (IVIG) be beneficial?|pdf=|usr=}}
+
{{tp|p=32304139|t=ä. Progress and Concept for COVID?19 Vaccine Development |pdf=|usr=}}
+
{{tp|p=32213152|t=2020. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?|pdf=|usr=}}
+
{{tp|p=32299796|t=2020. Antirheumatic agents in covid-19: is IL-6 the right target?|pdf=|usr=}}
+
{{ttp|p=32376613|t=2020. Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025) |pdf=|usr=}}
+
{{tp|p=32366720|t=2020. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved  drugs |pdf=|usr=}}
+
{{tp|p=32312781|t=2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 |pdf=|usr=}}
+
{{tp|p=32205349|t=2020. Updated Approaches against SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32229155|t=2020. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?|pdf=|usr=}}
+
{{tp|p=32339387|t=2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin |pdf=|usr=}}
+
{{tp|p=32282033|t=2020. Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic |pdf=|usr=}}
+
{{tp|p=32362106|t=2020. Management of conjunctivitis during the COVID-19 pandemic 2020 |pdf=|usr=}}
+
{{tp|p=32302379|t=2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients |pdf=|usr=}}
+
{{tp|p=32366511|t=2020. Developing a vaccine for covid-19 |pdf=|usr=}}
+
{{tp|p=32357949|t=2020. Covid-19: Remdesivir is helpful but not a wonder drug, say researchers |pdf=|usr=}}
+
{{tp|p=32217607|t=2020. Covid-19: what treatments are being investigated?|pdf=|usr=}}
+
{{tp|p=32217555|t=2020. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients |pdf=|usr=}}
+
{{tp|p=32209549|t=2020. Covid-19: trials of four potential treatments to generate "robust data" of what works |pdf=|usr=}}
+
{{tp|p=32340998|t=2020. Covid-19: What do we know so far about a vaccine?|pdf=|usr=}}
+
{{tp|p=32321732|t=2020. Remdesivir in covid-19 |pdf=|usr=}}
+
{{tp|p=32359080|t=2020. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?|pdf=|usr=}}
+
{{tp|p=32304110|t=2020. Dosing will be a key success factor in repurposing antivirals for COVID-19 |pdf=|usr=}}
+
{{ttp|p=32369628|t=2020. Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date |pdf=|usr=}}
+
{{tp|p=32369612|t=2020. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma |pdf=|usr=}}
+
{{tp|p=32368792|t=2020. Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2 |pdf=|usr=}}
+
{{ttp|p=32358833|t=2020. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development  IUPHAR Review 29 |pdf=|usr=}}
+
{{tp|p=32329520|t=2020. Current pharmacological treatments for COVID-19: What s next?|pdf=|usr=}}
+
{{tp|p=32371479|t=2020. Cytokine Storm Drugs Move from CAR T to COVID-19 |pdf=|usr=}}
+
{{tp|p=32303509|t=2020. Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19 |pdf=|usr=}}
+
{{tp|p=32276929|t=2020. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?|pdf=|usr=}}
+
{{ttp|p=32324951|t=2020. Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics |pdf=|usr=}}
+
{{tp|p=32245590|t=2020. Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP) |pdf=|usr=}}
+
 
+
{{tp|p=32379692|t=ä. Traditional Chinese Medicine treatment of COVID-19 |pdf=|usr=}}
+
{{tp|p=32379639|t=2020. Herbal medicine for treatment of children diagnosed with COVID-19: A review of guidelines |pdf=|usr=}}
+
{{ttp|p=32271624|t=2020. Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis?|pdf=|usr=}}
+
{{tp|p=32333649|t=2020. The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene |pdf=|usr=}}
+
{{tp|p=32378737|t=2020. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of  COVID-19 |pdf=|usr=}}
+
{{tp|p=32356569|t=2020. Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology |pdf=|usr=}}
+
{{tp|p=32246834|t=2020. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection |pdf=|usr=}}
+
{{tp|p=32350860|t=2020. Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32348551|t=2020. Response to: Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An  Integrative Modeling Approach for Effective Drug Repurposing: Quantitative Clinical Pharmacology Input to SARS-CoV-2 Therapeutics Should Be Based on Robust  Data |pdf=|usr=}}
+
{{tp|p=32302411|t=2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and  Use in COVID-19 |pdf=|usr=}}
+
{{tp|p=32167153|t=2020. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?|pdf=|usr=}}
+
{{tp|p=32345063|t=2020. Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic |pdf=|usr=}}
+
{{tp|p=32315229|t=2020. COVID-19 and the CRISPR Community Response |pdf=|usr=}}
+
{{tp|p=32321407|t=2020. Hispidin and Lepidine E: two Natural Compounds and Folic acid as Potential Inhibitors of 2019-novel coronavirus Main Protease (2019-nCoVMpro), molecular docking and SAR study |pdf=|usr=}}
+
{{ttp|p=32297571|t=2020. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus|pdf=|usr=}}
+
{{tp|p=32334502|t=2020. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral  Treatment|pdf=|usr=}}
+
{{tp|p=32133962|t=2020. Effective Chemicals against Novel Coronavirus (COVID-19) in China |pdf=|usr=}}
+
{{tp|p=32314492|t=ä. Doxycycline, a widely used antibiotic in dermatology with a possible anti?inflammatory action against IL?6 in COVID?19 outbreak |pdf=|usr=}}
+
{{tp|p=32237190|t=ä. What does androgenetic alopecia have to do with COVID?19? An insight into a potential new therapy |pdf=|usr=}}
+
{{tp|p=32227357|t=ä. COVID?19 treatment by repurposing drugs until the vaccine is in sight |pdf=|usr=}}
+
{{tp|p=32377559|t=ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus |pdf=|usr=}}
+
{{tp|p=32374010|t=2020. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19?|pdf=|usr=}}
+
{{tp|p=32374009|t=2020. Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19 |pdf=|usr=}}
+
{{tp|p=32369103|t=ä. Sacubitril/valsartan in COVID-19 patients: the need for trials |pdf=|usr=}}
+
{{tp|p=32373994|t=2020. Could host cell receptor alteration prevent SARS-CoV-2 viral entry? - Hype or hope |pdf=|usr=}}
+
{{tp|p=32373992|t=2020. MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment |pdf=|usr=}}
+
{{tp|p=32373991|t=2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking |pdf=|usr=}}
+
{{tp|p=32362193|t=2020. Quadruple therapy for asymptomatic COVID-19 infection patients |pdf=|usr=}}
+
{{tp|p=32366131|t=2020. Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine |pdf=|usr=}}
+
{{tp|p=32336007|t=2020. DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?|pdf=|usr=}}
+
{{tp|p=32224164|t=2020. COVID-19 and diabetes: Can DPP4 inhibition play a role?|pdf=|usr=}}
+
{{tp|p=32278585|t=2020. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab |pdf=|usr=}}
+
{{ttp|p=32337769|t=2020. (tt bradykinin) Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32352361|t=2020. Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists |pdf=|usr=}}
+
{{tp|p=32359101|t=2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications |pdf=|usr=}}
+
{{tp|p=32281695|t=2020. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases |pdf=|usr=}}
+
{{tp|p=32379896|t=2020. Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs |pdf=|usr=}}
+
{{tp|p=31690127|t=2019. Identification of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach |pdf=|usr=}}
+
{{tp|p=32157732|t=ä. Harnessing the immune system via Fc?R function in immune therapy: a pathway to next?gen mAbs |pdf=|usr=}}
+
 
+
{{tp|p=32298218|t=2020. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19 |pdf=|usr=}}
+
{{tp|p=32317431|t=2020. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future |pdf=|usr=}}
+
{{tp|p=32370727|t=2020. SARS-CoV-2 & Covid-19: Key-Roles of the  Renin-Angiotensin  System / Vitamin D Impacting Drug and Vaccine Developments |pdf=|usr=}}
+
{{ttp|p=32377694|t=2020. Towards effective COVID19 vaccines: Updates, perspectives and challenges (Review) |pdf=|usr=}}
+
{{tp|p=32338559|t=2020. Low dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence?|pdf=|usr=}}
+
{{tp|p=32319538|t=2020. Zinc and respiratory tract infections: Perspectives for COVID19 (Review) |pdf=|usr=}}
+
{{tp|p=32310190|t=2020. Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19 |pdf=|usr=}}
+
{{tp|p=32347747|t=2020. Can melatonin reduce the severity of COVID-19 pandemic?|pdf=|usr=}}
+
{{tp|p=32268052|t=2020. Vitamin D, Covid-19 and Children |pdf=|usr=}}
+
{{tp|p=32268051|t=2020. Optimisation of Vitamin D Status for Enhanced Immuno-protection Against Covid-19 |pdf=|usr=}}
+
{{tp|p=32338164|t=2020. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective |pdf=|usr=}}
+
{{tp|p=32306860|t=2020. Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations |pdf=|usr=}}
+
{{tp|p=32306822|t=2020. Peptide-like and small-molecule inhibitors against Covid-19 |pdf=|usr=}}
+
{{tp|p=32340551|t=2020. Natural products may interfere with SARS-CoV-2 attachment to the host cell |pdf=|usr=}}
+
{{tp|p=32329419|t=2020. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach |pdf=|usr=}}
+
{{tp|p=32329408|t=2020. Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease |pdf=|usr=}}
+
{{tp|p=32362235|t=2020. Understanding the binding affinity of ''noscapines'' with protease of SARS-CoV-2 for  COVID-19 using MD simulations at different temperatures |pdf=|usr=}}
+
{{tp|p=32362243|t=2020. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target |pdf=|usr=}}
+
{{tp|p=32364041|t=2020. Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32364011|t=2020. FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main  protease, essential for viral replication |pdf=|usr=}}
+
{{tp|p=32362217|t=2020. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria |pdf=|usr=}}
+
{{tp|p=32362245|t=2020. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study |pdf=|usr=}}
+
{{tp|p=32345124|t=2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets |pdf=|usr=}}
+
{{tp|p=32340562|t=2020. A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32376368|t=ä. Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach |pdf=|usr=}}
+
{{tp|p=32228825|t=2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1 |pdf=|usr=}}
+
{{tp|p=32171193|t=2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by  Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies |pdf=|usr=}}
+
{{tp|p=32367767|t=2020. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL(pro)): an in silico screening of alkaloids and terpenoids from African medicinal plants |pdf=|usr=}}
+
{{tp|p=32238094|t=2020. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach |pdf=|usr=}}
+
{{tp|p=32345140|t=2020. Stilbene-based natural compounds as promising drug candidates against COVID-19 |pdf=|usr=}}
+
{{tp|p=32266867|t=2020. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain) |pdf=|usr=}}
+
{{tp|p=32248766|t=2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19 |pdf=|usr=}}
+
{{tp|p=32349031|t=2020. Role of Dipeptidyl Peptidase 4 Inhibitors in Diabetic Patients with Coronavirus-19 Infection |pdf=|usr=}}
+
{{tp|p=32173110|t=2020. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 |pdf=|usr=}}
+
{{tp|p=32379348|t=2020. 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics |pdf=|usr=}}
+
 
+
{{tp|p=32227493|t=ä. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID?19 |pdf=|usr=}}
+
{{tp|p=32219882|t=ä. Controversial treatments: An updated understanding of the coronavirus disease 2019 |pdf=|usr=}}
+
{{tp|p=32104907|t=ä. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus?A possible reference for coronavirus disease?19 treatment option |pdf=|usr=}}
+
{{tp|p=32108352|t=ä. Clinical trial analysis of 2019?nCoV therapy registered in China |pdf=|usr=}}
+
{{tp|p=32379346|t=2020. ACE2 Activators for the Treatment of Covid 19 Patients |pdf=|usr=}}
+
{{tp|p=32374457|t=2020. The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections |pdf=|usr=}}
+
{{tp|p=32369191|t=2020. Tocilizumab for the treatment of severe coronavirus disease 2019 |pdf=|usr=}}
+
{{tp|p=32356910|t=2020. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review |pdf=|usr=}}
+
{{tp|p=32232976|t=2020. CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32176361|t=2020. Potentially repurposing adamantanes for COVID-19 |pdf=|usr=}}
+
{{tp|p=32270515|t=2020. Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?|pdf=|usr=}}
+
{{tp|p=32253759|t=2020. Tocilizumab treatment in COVID-19: A single center experience |pdf=|usr=}}
+
{{tp|p=32347974|t=2020. Metformin and COVID-19: A novel deal of an Old Drug |pdf=|usr=}}
+
{{tp|p=32239514|t=ä. Comments on Zhang et al: Clinical trial analysis of 2019?nCoV therapy registered  in China |pdf=|usr=}}
+
{{tp|p=32236562|t=2020. Treating COVID-19 with Chloroquine |pdf=|usr=}}
+
{{ttp|p=32378064|t=ä. Feasibility of Therapeutic Effects of the Cholinergic Anti-Inflammatory Pathway on COVID-19 Symptoms |pdf=|usr=}}
+
{{tp|p=32320059|t=2020. Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history  and mechanism |pdf=|usr=}}
+
{{tp|p=32297988|t=2020. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis |pdf=|usr=}}
+
{{tp|p=32297985|t=2020. Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China |pdf=|usr=}}
+
{{tp|p=32297987|t=2020. Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection |pdf=|usr=}}
+
{{tp|p=32293713|t=2020. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China |pdf=|usr=}}
+
{{tp|p=32285942|t=2020. Defining Protective Epitopes for COVID-19 Vaccination Models |pdf=|usr=}}
+
{{tp|p=32281679|t=2020. COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy |pdf=|usr=}}
+
{{tp|p=32302456|t=2020. Potential of heparin and nafamostat combination therapy for COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32376627|t=2020. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity |pdf=|usr=}}
+
{{tp|p=32359402|t=2020. Considering BCG vaccination to reduce the impact of COVID-19 |pdf=|usr=}}
+
{{tp|p=32380023|t=ä. Immunomodulation in COVID-19 |pdf=|usr=}}
+
{{tp|p=32367857|t=2020. Safety of an immunomodulator Mycobacterium w in COVID-19 |pdf=|usr=}}
+
{{tp|p=32367847|t=2020. Nasopharyngeal wash in preventing and treating upper respiratory tract infections: Could it prevent COVID-19?|pdf=|usr=}}
+
{{tp|p=32371362|t=2020. Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients |pdf=|usr=}}
+
{{tp|p=32366816|t=2020. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development |pdf=|usr=}}
+
{{tp|p=32376359|t=ä. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32219429|t=2020. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges |pdf=|usr=}}
+
{{tp|p=32352484|t=2020. Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19 |pdf=|usr=}}
+
{{tp|p=32208486|t=2020. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical  Trials During Pandemics |pdf=|usr=}}
+
{{tp|p=32297900|t=2020. Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis |pdf=|usr=}}
+
{{tp|p=32282022|t=2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review |pdf=|usr=}}
+
{{tp|p=32347894|t=2020. The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm |pdf=|usr=}}
+
{{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}}
+
{{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}}
+
{{tp|p=32251638|t=2020. Baricitinib for COVID-19: a suitable treatment?|pdf=|usr=}}
+
{{tp|p=32251639|t=2020. Baricitinib for COVID-19: a suitable treatment? - Authors  reply |pdf=|usr=}}
+
{{ttp|p=32240961|t=2020. Routine childhood immunization may protect against COVID-19 |pdf=|usr=}}
+
{{tp|p=32372435|t=2020. Drug repurposing in the era of COVID-19: a call for leadership and government investment |pdf=|usr=}}
+
{{tp|p=32266987|t=2020. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32324177|t=2020. Some drugs for COVID-19 |pdf=|usr=}}
+
{{tp|p=32162456|t=ä. Rapid Identification of Potential Inhibitors of SARS?CoV?2 Main Protease by Deep  Docking of 1 3?Billion Compounds |pdf=|usr=}}
+
{{tp|p=32379955|t=ä. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 |pdf=|usr=}}
+
{{tp|p=32375002|t=ä. Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery |pdf=|usr=}}
+
{{ttp|p=32378459|t=2020. Application of nanomaterials in treatment, anti-infection and detection of coronaviruses |pdf=|usr=}}
+
{{ttp|p=32363750|t=2020. A Chemographic Audit of anti-Coronavirus Structure-Activity Information from Public Databases (ChEMBL) |pdf=|usr=}}
+
{{tp|p=32369286|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19  Reply |pdf=|usr=}}
+
{{tp|p=32227757|t=2020. Developing Covid-19 Vaccines at Pandemic Speed |pdf=|usr=}}
+
{{tp|p=32289216|t=2020. Drug Evaluation during the Covid-19 Pandemic |pdf=|usr=}}
+
{{tp|p=32332765|t=2020. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig |pdf=|usr=}}
+
{{tp|p=32273604|t=2020. Lopinavir-ritonavir in severe COVID-19 |pdf=|usr=}}
+
{{tp|p=32273591|t=2020. The COVID-19 vaccine development landscape |pdf=|usr=}}
+
{{tp|p=32269311|t=2020. Coordinating the COVID-19 pipeline |pdf=|usr=}}
+
{{tp|p=32127666|t=2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) |pdf=|usr=}}
+
{{tp|p=32376938|t=2020. China is promoting coronavirus treatments based on unproven traditional medicines |pdf=|usr=}}
+
{{tp|p=32272481|t=2020. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors |pdf=|usr=}}
+
{{tp|p=32350436|t=2020. Hopes rise for coronavirus drug remdesivir |pdf=|usr=}}
+
{{tp|p=32355243|t=2020. Scores of coronavirus vaccines are in competition - how will scientists choose the best?|pdf=|usr=}}
+
{{tp|p=32353859|t=2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |pdf=|usr=}}
+
{{tp|p=32300225|t=2020. On the front lines of the coronavirus-vaccine battle |pdf=|usr=}}
+
{{tp|p=32346146|t=2020. The race for coronavirus vaccines: a graphical guide |pdf=|usr=}}
+
 
+
{{tp|p=32377399|t=2020. COVID-19 vaccines: breaking record times to first-in-human trials |pdf=|usr=}}
+
{{tp|p=32297843|t=2020. Oligonucleotides and the COVID-19 Pandemic: A Perspective |pdf=|usr=}}
+
{{tp|p=32380200|t=ä. In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32275178|t=2020. Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease |pdf=|usr=}}
+
{{tp|p=32216577|t=2020. Artificial intelligence and machine learning to fight COVID-19 |pdf=|usr=}}
+
{{tp|p=32380051|t=ä. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence |pdf=|usr=}}
+
{{tp|p=32352615|t=2020. Povidone-iodine gargle as a prophylactic intervention to interrupt the transmission of SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32209313|t=2020. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws |pdf=|usr=}}
+
{{tp|p=32285489|t=2020. Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity |pdf=|usr=}}
+
{{tp|p=32267566|t=2020. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19 |pdf=|usr=}}
+
{{tp|p=32267560|t=2020. Considerations for Statin Therapy in Patients with COVID-19 |pdf=|usr=}}
+
{{tp|p=32259313|t=2020. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 |pdf=|usr=}}
+
{{tp|p=32281114|t=2020. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient |pdf=|usr=}}
+
{{tp|p=32296012|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}}
+
{{tp|p=32295694|t=2020. COVID-19 vaccination clinical trials should consider multiple doses of BCG |pdf=|usr=}}
+
{{tp|p=32326830|t=2020. Photobiomodulation and Antiviral Photodynamic Therapy as a Possible Novel Approach in COVID-19 Management |pdf=|usr=}}
+
{{tp|p=32330404|t=2020. Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?|pdf=|usr=}}
+
{{tp|p=32352594|t=2020. Phytotherapic compounds against coronaviruses: Possible streams for future research |pdf=|usr=}}
+
{{tp|p=32347602|t=2020. Should we try the antiinflammatory natural product, celastrol, for COVID-19?|pdf=|usr=}}
+
{{tp|p=32350134|t=2020. Effective treatment of severe COVID-19 patients with tocilizumab |pdf=|usr=}}
+
{{tp|p=32365207|t=ä. Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report |pdf=|usr=}}
+
{{tp|p=32314850|t=2020. Melatonin: Roles in influenza, Covid?19, and other viral infections |pdf=|usr=}}
+
{{tp|p=32374874|t=ä. COVID-19: an unexpected indication for anti-rheumatic therapies?|pdf=|usr=}}
+
{{tp|p=32376603|t=ä. Development of an inactivated vaccine candidate for SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32352871|t=2020. A Radiation Mitigator as a Potential Treatment for COVID-19 |pdf=|usr=}}
+
{{tp|p=32273254|t=2020. Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic |pdf=|usr=}}
+
{{tp|p=32167254|t=2020. Epidemie de coronavirus et polemique sur la chloroquine |pdf=|usr=}}
+
{{tp|p=32270942|t=2020. Covid-19, dans les brouillards francais de l'hydroxychloroquine |pdf=|usr=}}
+
{{tp|p=32301315|t=2020. Covid-19, dans les brouillards de l'hydroxychloroquine (2) |pdf=|usr=}}
+
{{tp|p=32301312|t=2020. Vaccins anti-covid-19 : les recherches de johnson & johnson, sanofi et pasteur |pdf=|usr=}}
+
{{tp|p=32355008|t=2020. COVID-19 shot protects monkeys |pdf=|usr=}}
+
{{tp|p=32292113|t=2020. Stem Cell?Based Therapy for Coronavirus Disease 2019 |pdf=|usr=}}
+
{{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}}
+
{{tp|p=32360327|t=ä. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence |pdf=|usr=}}
+
{{tp|p=32302280|t=2020. Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department |pdf=|usr=}}
+
{{tp|p=32220178|t=2020.  Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019  |pdf=|usr=}}
+
{{tp|p=32374891|t=2020. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations  for clinical trial design |pdf=|usr=}}
+
{{tp|p=32374890|t=2020. COVID-19 convalescent plasma: phase 2 |pdf=|usr=}}
+
{{tp|p=32245869|t=2020. Possible treatment of Covid-19 with a therapeutic vaccine |pdf=|usr=}}
+
{{tp|p=32221001|t=2020. Possible method for the production of a Covid-19 vaccine |pdf=|usr=}}
+
{{tp|p=32324899|t=2020. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy |pdf=|usr=}}
+
{{tp|p=32319102|t=2020. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma |pdf=|usr=}}
+
{{tp|p=32240545|t=2020. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?|pdf=|usr=}}
+
{{tp|p=32268018|t=2020.  Analysis of medication characteristics of traditional Chinese medicine in treating coronavirus disease-19 based on data mining  |pdf=|usr=}}
+
{{tp|p=32281335|t=2020.  Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus  |pdf=|usr=}}
+
{{tp|p=32281333|t=2020.  Analysis of property and efficacy of traditional Chinese medicine in staging revention and treatment of coronavirus disease 2019  |pdf=|usr=}}
+
{{tp|p=32281332|t=2020.  Study on medication regularity of traditional Chinese medicine in treatment of COVID-19 based on data mining  |pdf=|usr=}}
+
{{tp|p=32281331|t=2020.  Analysis on pattern of prescriptions and syndromes of traditional Chinese medicine for prevention and treatment of COVID-19  |pdf=|usr=}}
+
{{tp|p=32281330|t=2020.  Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019  |pdf=|usr=}}
+
{{ttp|p=32281329|t=2020.  Study on treatment of "cytokine storm" by anti-2019-nCoV prescriptions based on  arachidonic acid metabolic pathway  |pdf=|usr=}}
+
{{tp|p=32281328|t=2020.  Study on screening potential traditional Chinese medicines against 2019-nCoV based on Mpro and PLP  |pdf=|usr=}}
+
{{tp|p=32281327|t=2020.  Rapid establishment of traditional Chinese medicine prevention and treatment of  2019-nCoV based on clinical experience and molecular docking  |pdf=|usr=}}
+
{{tp|p=32164085|t=2020.  Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia  |pdf=|usr=}}
+
{{tp|p=32164084|t=2020.  Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia  |pdf=|usr=}}
+
{{tp|p=32164080|t=2020.  Potential antiviral therapeutics for 2019 Novel Coronavirus  |pdf=|usr=}}
+
{{tp|p=32164081|t=2020.  Pharmacotherapeutics for the new coronavirus pneumonia  |pdf=|usr=}}
+
{{tp|p=32164077|t=2020.  Pharmacotherapeutic about the new coronavirus pneumonia  |pdf=|usr=}}
+
{{tp|p=32114746|t=2020.  Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer  |pdf=|usr=}}
+
{{tp|p=32234130|t=2020.  Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)  |pdf=|usr=}}
+

Aktuelle Version vom 21. September 2021, 06:15 Uhr

homepage
hottest actual papers
 P further streaming-in related content is here
 CHERRYPICKING STUDIES IS NOT SCIENCE
Reviews on covid drug development


PHA related options:


A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
Paper is (not yet in PubMed) :

credentials to Marinus Brandl who told us about it today. based on e.g.

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
=======================================================================================
COVID19 is now a CURABLE disease !!!
=======================================================================================

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis